StockNews.com Initiates Coverage on Jounce Therapeutics (NASDAQ:JNCE)

Investment analysts at StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James cut shares of Jounce Therapeutics from an “outperform” rating to a “market […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Robert Schreiber ,Padmanee Sharma ,Piper Sandler ,Thomasf Gajewski ,Jamesp Allison ,Louism Weiner ,Raymond James ,Kevinc Tang ,Jounce Therapeutics Company Profile ,Sumitomo Mitsui Financial Group ,Connor Clark Lunn Investment Management Ltd ,Jounce Therapeutics Inc ,Renaissance Technologies ,Securities Exchange Commission ,Balyasny Asset Management ,Investment Advisers ,Jounce Therapeutics ,Get Rating ,Therapeutics Trading Down ,Director Richard ,Exchange Commission ,Asset Management ,Lunn Investment Management ,Jounce Therapeutics Daily ,Nasdaq Jnce ,Jnce ,Medical ,Initiated Coverage ,Stocknews Com ,